Details for Patent: 11,707,451
✉ Email this page to a colleague
Which drugs does patent 11,707,451 protect, and when does it expire?
Patent 11,707,451 protects MYRBETRIQ and is included in one NDA.
Protection for MYRBETRIQ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eight patent family members in seven countries.
Drugs Protected by US Patent 11,707,451
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-001 | Jun 28, 2012 | AB | RX | Yes | Yes | 11,707,451*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Apgdi | MYRBETRIQ | mirabegron | TABLET, EXTENDED RELEASE;ORAL | 202611-002 | Jun 28, 2012 | AB | RX | Yes | Yes | 11,707,451*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,707,451
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2554168 | ⤷ Subscribe | |||
| Spain | 2665467 | ⤷ Subscribe | |||
| Japan | 5849947 | ⤷ Subscribe | |||
| Japan | WO2011122524 | ⤷ Subscribe | |||
| Poland | 2554168 | ⤷ Subscribe | |||
| Portugal | 2554168 | ⤷ Subscribe | |||
| Turkey | 201802207 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
